Rhythm Pharmaceuticals

General Information

We are a biopharmaceutical company focused on the development and commercialization of peptide therapeutics for the treatment of rare genetic deficiencies that result in life-threatening metabolic disorders. Our lead peptide product candidate is setmelanotide, a potent, first-in-class melanocortin-4 receptor, or MC4R, agonist for the treatment of rare genetic disorders of obesity. We believe setmelanotide, for which we have exclusive worldwide rights, has the potential to serve as replacement therapy for the treatment of melanocortin-4, or MC4, pathway deficiencies. MC4 pathway deficiencies result in the disruption of satiety signals and energy homeostasis in the body, which, in turn, leads to intense feelings of hunger and to obesity.

Employees: 15
Founded: 2013
Contact Information
Address 500 Boylston Street, 11th Floor, Boston, MA 02116, US
Phone Number (857) 264-4280
Web Address http://www.rhythmtx.com
View Prospectus: Rhythm Pharmaceuticals
Financial Information
Market Cap $454.92mil
Revenues $0 mil (last 12 months)
Net Income $-31.9 mil (last 12 months)
IPO Profile
Symbol RYTM
Exchange NASDAQ
Shares (millions): 7.1
Price range $17.00 - $17.00
Est. $ Volume $119.9 mil
Manager / Joint Managers Morgan Stanley/ BofA Merrill Lynch/ Cowen
CO-Managers Needham
Expected To Trade: 10/5/2017
Status: Priced
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change